LEGN Nov 2024 45.000 put
| Previous close | 5.70 |
| Open | 5.90 |
| Bid | 4.20 |
| Ask | 7.30 |
| Strike | 45.00 |
| Expiry date | 2024-11-15 |
| Day's range | 5.70 - 5.90 |
| Contract range | N/A |
| Volume | |
| Open interest | 70 |
Insider MonkeyDoes Legend Biotech (LEGN) Have a Long Runway for Growth?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Focus Growth Strategy” first-quarter investor letter. A copy of the letter can be downloaded here. In the first quarter, the strategy returned 11.72% (gross) and 11.49% (net) compared to 9.50% for the Russell Midcap Growth Index. The first-quarter performance was barbelled, particularly for U.S. […]
Business WireLegend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
SOMERSET, N.J., June 03, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today results for the first time from the Phase 2 CARTITUDE-2 Cohort D study in multiple myeloma patients. Results showed patients with less than a complete response (CR) after front-line autologous stem cell transplant (ASCT) experienced deep and durable responses following a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) with or without lena
Business WireLegend Biotech to Participate in the Jefferies Global Healthcare Conference
SOMERSET, N.J., May 29, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 6, 2024, at 10:30 a.m. ET.
